A Phase 3 Trial of the Efficacy and Safety of Oral Recombinant Calcitonin: The Oral Calcitonin in Postmenopausal Osteoporosis
Accordingly, the inhibition of osteoclast differentiation and activation would be a therapeutic strategy for postmenopausal osteoporosis
14) It is approved for the treatment of postmenopausal osteoporosis
, osteoporosis in men, and for patients with GIO.
Otero concluded that a programme of physical exercise based on low-intensity strength exercises and exercises involving static and dynamic balance, carried out three days per week in one-hour sessions over a 6-month period, leads to significant improvements in muscular strength in the upper and lower limbs and in static and dynamic balance in women with postmenopausal osteoporosis
FDA-Approved Drugs for the Treatment and/or Prevention of Postmenopausal Osteoporosis
Indications Drug Class Drug Name Prevention Treatment Bisphosphonates Alendronate X X Risedronate X X Ibandronate, oral X X Ibandronate, IV X Zoledronate X X Hormonal Systemic estrogen X Salmon calcitonin X Teriparatide X Selective estrogen Raloxifene X X receptor modulator (SERM) Biologics Denosumab X FDA=US Food and Drug Administration,; IV=intravenous.
In July 2009, Amgen and GlaxoSmithKline (GSK) announced a collaboration agreement to jointly commercialize Prolia for postmenopausal osteoporosis
in Europe, Australia, New Zealand and Mexico once the product is approved in these countries.
Denosumab is being studied in a range of bone loss conditions including postmenopausal osteoporosis
and bone loss in patients undergoing hormone ablation for prostate and breast cancer.
AclastaA is already approved in more than 50 countries, including the EU, US and Canada, for use in patients with Paget's disease, a chronic disorder that causes abnormal bone growth, and postmenopausal osteoporosis
Fortical(R) presents an exciting new option for women with postmenopausal osteoporosis
," said Phill Dritsas, vice president, Marketing and Sales for Upsher-Smith.
Vertebral fracture risk reduction was a primary outcome measure in the postmenopausal osteoporosis
studies and was a secondary outcome measure (along with change in BMD) assessed in the glucocorticoid-induced osteoporosis studies.
In postmenopausal osteoporosis
, the hormonal changes associated with menopause cause the normal balance between bone resorption (loss) and formation to be thrown off, with increased resorption resulting in less dense bones that are more prone to fracture.
Ipriflavone in the treatment of postmenopausal osteoporosis
," JAMA, 2001, 28501).
Now, we have the molecular explanation for postmenopausal osteoporosis
," says Penninger.
1 Table of Contents 2 Postmenopausal Osteoporosis
Therapeutics: Introduction 3 Postmenopausal Osteoporosis
Therapeutics: Market Characterization 4 Postmenopausal Osteoporosis
Therapeutics: Competitive Assessment 5 Postmenopausal Osteoporosis
Therapeutics: Pipeline Assessment 6 Postmenopausal Osteoporosis
Therapeutics: Clinical Trials Mapping 7 Postmenopausal Osteoporosis
Therapeutics: Strategic Assessment 8 Postmenopausal Osteoporosis
Therapeutics: Future Players 9 Postmenopausal Osteoporosis
Therapeutics: Licensing & Partnership Deals 10 Postmenopausal Osteoporosis
iv] Postmenopausal osteoporosis
has a huge impact on healthcare budgets, which are already expected to double for osteoporosis by the year 2050.